6621.TWO UniPharma Co., Ltd.

Healthcare Drug Manufacturers - Specialty & Generic Taiwan OTC Exchange
12.00 TWD
Close of Nov 6, 2026
10.50 16.00
Market cap
TWD 426M
P/E
-
P/B
2.25x
ROE
-17.6%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is 6621.TWO undervalued?

Graham number

The Graham number of UniPharma Co., Ltd. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

UniPharma Co., Ltd. fundamental analysis

No fundamental analysis for UniPharma Co., Ltd. yet.

UniPharma Co., Ltd. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About UniPharma Co., Ltd.

UniPharma Co., Ltd. engages in the distribution of pharmaceutical drugs, medical devices, and diagnostic tests in Taiwan. It provides diagnostic tests in areas of oncology, gynecology, orthopedics, neurology, anesthesiology, and cardiology. The company offers Adept reduction solution; bain, esmolol HCI, and naloxone anesthesia injections; Elisa DR-70 test for in-vitro diagnostics of tumors; and fomeject antidote injection, as well as drug development, research and developmen…

Full company profile